# 9. Executive Readiness Summary — Clinical Workspace 2.0

**Prepared for:** CEO, CIO, Medical Director, Legal Affairs, Compliance, Information Security, Quality, Clinical Governance, Operations, External Auditor  
**Date:** 2026-06-26  
**Status:** Package complete; production release blocked pending resolution of identified items.

---

## 1. What We Are Releasing

Clinical Workspace 2.0 is a prototype-ready intelligent informed consent workflow. It gives physicians a decision-support workspace that resolves the right consent package, education material, risk disclosures, and required participants (guardian, interpreter, witness) for a selected patient and procedure. Patients then review the information in Arabic or English, ask questions, make a voluntary decision, and sign — with every critical action recorded in an auditable timeline.

The current validation scope is limited to the isolated prototype route `/prototype/clinical-workspace-2` using deterministic mock data. No production routes, signing services, OTP/SMS gateways, PDF engines, or WathiqNote flows are modified.

---

## 2. Why It Matters

- **Patient safety:** Alerts for allergy, medication, high-risk procedure, expired package, and updated guideline are surfaced and must be acknowledged before a consent can be sent.
- **Legal defensibility:** Refusals are captured with signature, acknowledgment, and a dedicated audit event; evidence exports contain hashes and actor attribution.
- **Equity of care:** Full Arabic (RTL) and English (LTR) support, plus text-size and high-contrast controls, help patients with different language and accessibility needs.
- **Operational efficiency:** A single workspace reduces the time physicians spend locating the right consent form and education material.

---

## 3. What Is Ready Now

| Area | Readiness |
|------|-----------|
| UAT planning and test scripts | Complete |
| Clinical scenario library | Complete (11 scenarios) |
| Acceptance criteria | Complete (64 criteria) |
| Training materials | Complete for physicians, nurses, legal reviewers, admins, and patients |
| Deployment and rollback checklists | Complete |
| Operational runbook and support handover | Complete |
| Hypercare plan for first 30 days | Complete |
| Risk, known issues, and open risk registers | Complete |
| Production validation matrix | Complete |
| Stakeholder sign-off templates | Complete |

---

## 4. What Is Not Ready for Production

| Item | Impact | Path Forward |
|------|--------|--------------|
| Patient remote signing route (`/sign/[token]/workflow`) | High — real patients cannot sign remotely without this route. | Engineering ticket to build the route behind a feature flag. |
| Live Clinical Knowledge Engine integration | Medium — mock engine may differ from production behavior. | Validate mapping contract and alerts against live CKE. |
| Load and concurrency testing | Medium — unknown behavior at peak volume. | Execute in staging before pilot. |
| Legal review of refusal copy | High — potential defensibility exposure. | Route final copy through Legal Affairs. |
| Third-party accessibility audit | Medium — WCAG conformance not independently verified. | Schedule audit before full rollout. |

---

## 5. Validation Evidence

- **Smoke script:** `qa-screenshots/capture-workspace-2-flow.mjs` exercises happy path, refusal path, and clinical alerts.
- **Playwright spec:** `apps/web/tests/clinical-workspace-2.spec.ts` covers acceptance, refusal, and alert-blocking behavior.
- **Mock data:** Deterministic patients, encounters, procedures, risks, and alerts in `apps/web/src/app/prototype/clinical-workspace-2/lib/mock-data.ts`.
- **Screenshots:** Generated in `qa-screenshots/` after smoke-script execution.

---

## 6. Governance and Constraints

- **No deployment, merge, or production modification** is authorized as part of this package.
- **No destructive migration** is required; the prototype uses client-side state.
- All changes remain **additive**.
- Rollback can be executed via feature flags and alias changes without deleting audit data or active sessions.

---

## 7. Recommendation

**GO WITH OBSERVATIONS** for controlled UAT and a time-bound prototype pilot.

**NO GO** for full production release until the remote signing route is built, refusal copy is legally approved, accessibility is independently verified, and load testing is complete.

---

## 8. Next Steps

1. Execute UAT using [01-uat-plan.md](./01-uat-plan.md) and [02-test-scripts.md](./02-test-scripts.md).
2. Run the smoke script and attach screenshots to the readiness report.
3. Create an engineering ticket for the remote signing route.
4. Complete legal review of refusal and patient-copy language.
5. Schedule third-party accessibility audit and staging load tests.
6. Reconvene the readiness review board after blockers are closed.

---

**Document owner:** Enterprise Readiness Lead  
**Review cadence:** Weekly during UAT/pilot; ad-hoc when blockers close.
